Nancy Chang joins Immix Biopharma board of directors

Immix Biopharma, Inc. (NASDAQ: IMMX) announced Nancy T. Chang has joined its board of directors. Chang previously served as CEO of Tanox, Inc., where she led development of several FDA-approved drugs.

During her tenure at Tanox, Chang oversaw development of XOLAIR for severe asthma, TROGARZO for HIV, and EBGLYSS for dermatitis. These drugs have generated combined sales exceeding $5 billion, according to the company statement.

Genentech/Roche acquired Tanox for $919 million. Eli Lilly and Co. currently commercializes EBGLYSS.

Chang's appointment coincides with her investment as a founding member of Goose Capital. Immix Biopharma develops cell therapies for AL Amyloidosis and other diseases.

The company's lead candidate NXC-201 is a BCMA-targeted CAR-T cell therapy being evaluated in the NEXICART-2 study for relapsed/refractory AL Amyloidosis. The FDA has awarded NXC-201 Regenerative Medicine Advanced Therapy designation and Orphan Drug Designation. The therapy also received Orphan Drug Designation from the European Medicines Agency.

Immix reported that NEXICART-2 met its primary endpoint at interim results presented at ASCO 2025.

You May Also Be Interested In

• Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
• Erasca reports Phase 1 data for ERAS-0015 in KRAS-mutant tumors
• Jones Ventures INTL Acquisition1 prices $200M IPO on Nasdaq